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ment by day one in shoulder and back pain when compared to
a lower dose of the same drug. Patients also reported statistically
signiﬁcant (p < 0.05) reduced pain while awake by day three,
improved overall pain by day two, global emotional improve-
ment by day three, and global physical improvement by day
seven. This improvement data was collected electronically using
a verbally administered numeric scale. RESULTS: In both cases,
these data would have been difﬁcult, if not impossible, to collect
reliably at the study site or via paper. Sponsor acceptance of
ePRO data is shown by a recent survey of 156 webinar regis-
trants that found that 36% indicated that they have included, or
intend to include, ePRO data in a regulatory submission as a
primary (22%) or secondary (14%) endpoint. CONCLUSIONS:
This session reviews the methods and associated research for ver-
bally orienting a study subject and verbally administering analog
scales in clinical trials. Additionially, regulatory acceptance of
electronic patient reported outcomes in clinical trials is explored
through real world case studies.
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OBJECTIVES: Prospective observational studies, which inform
on the effectiveness of interventions in natural settings, may com-
plement results from randomised clinical trials in the evaluation
of health technologies. However, observational studies are
subject to a number of potential methodological weaknesses,
mainly selection and observer bias. This analysis applies various
methods to control selection bias in the estimation of treatment
effects. We also address the issues of estimation and inference in
a multilevel setting. METHODS: We describe and compare the
use of regression methods, propensity score matching, ﬁxed-
effects models incorporating investigator characteristics, and a
multilevel, hierarchical model using Bayesian estimation tech-
niques in the control of selection bias. To illustrate these
methods, we have used data from the Schizophrenia Outpatient
Health Outcomes (SOHO) study, a large, prospective, observa-
tional study of health outcomes associated with the treatment of
schizophrenia. RESULTS: The methods used to adjust for dif-
ferences between treatment groups that could cause selection
bias yielded comparable results and reinforces the validity of the
ﬁndings. CONCLUSIONS: Observational studies, when prop-
erly conducted and when using adequate statistical methods, 
can provide valid information on the evaluation of health 
technologies.
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OBJECTIVES: Anxiety disorders like Social Anxiety Disorder
(SAD) or Generalised Anxiety Disorder (GAD) are severe,
chronic psychiatric disorders deﬁned in DSM-IV-TR needing
long-term treatment. However, they have been challenged as
being created by physicians and pharmaceutical companies.
Studies have shown that less than one-half received past year
mental health treatment. Patient Reported Outcome evaluation
is a useful way to evaluate the impairment caused by the diseases
from the patient’s perspective. METHODS: Two relapse pre-
vention randomised clinical trials in SAD and GAD were used,
excluding patients with other comorbidities. Quality of life was
assessed using the SF-36, consisting of eight dimensions: Physi-
cal Functioning (PF), Role-physical Limitations (RP), Bodily Pain
(BP), General Health (GH), Vitality (VT), Mental Health (MH),
Role-emotional Limitations (RE) and Social Functioning (SF).
Baseline SF-36 evaluations of patients with SAD or GAD were
compared to the published general population norms. RESULTS:
A total of 372 SAD patients and 333 GAD patients ﬁlled the SF-
36 at baseline. The SAD population was mostly impaired on the
mental dimensions compared to the general population norms,
with differences up to three times the Minimal Clinical Impor-
tant Difference (MCID): 50.4 ± 18.6 vs. 60.9 ± 21.0 (VT); 56.2
± 18.1 vs. 74.7 ± 18.1 (MH); 56.6 ± 40.1 vs. 81.3 ± 33.0 (RE);
50.4 ± 26.6 vs. 83.3 ± 22.7 (SF). In the GAD population, all
dimensions except PF were signiﬁcantly impaired. For RP, GH,
VT, MH, RE and SF the differences were up to 3 times the
MCID: 53.4 ± 41.3 vs. 82.0 ± 34.0; 56.4 ± 20.7 vs. 72.0 ± 20.3;
35.3 ± 18.6 vs. 60.9 ± 21.0; 42.4 ± 16.9 vs. 74.7 ± 18.1; 29.9 ±
36.0 vs. 81.3 ± 33.0; 48.6 ± 24.4 vs. 83.3 ± 22.7, respectively.
CONCLUSIONS: From the patient’s perspective the impairment
is severe, and differences with general population norms are
comparable with other diseases such as Major Depressive Dis-
order or Diabetes. These results suggest the substantial unmet
need for care should be considered seriously, especially in view
of available effective treatments for SAD and GAD.
PMH42
QUALITY OF LIFE IN PATIENTS WITH BIPOLAR DISORDER IN
5 EUROPEAN COUNTRIES
Leeuwenkamp O1, Perry R2, Morlock R3, Jones E2,Taylor T4
1Organon International Inc, Molenstraat, Oss,The Netherlands,
2Adelphi Group Products, Bollington, Cheshire, UK, 3Pﬁzer Inc, New
York, NY, USA, 4Pﬁzer, Ann Arbor, MI, USA
OBJECTIVES: To provide information on patient-reported
quality of life for patients with bipolar disorder in ﬁve European
countries. METHODS: Physicians in France, Germany, Italy,
Spain, and the UK who managed at least ten patients with
bipolar disorder within the preceding six months were invited to
complete a questionnaire concerning their patients’ clinical status
and therapy. Patients of these physicians were also invited to
complete a questionnaire that included the Euroqol EQ-5D, a 5-
item questionnaire assessing quality of life in ﬁve key areas:
mobility, self-care, usual activities, pain/discomfort, and anxiety/
depression. Patient responses to the 5 EQ-5D items were used to
generate EQ-5D utility scores. The patients were also asked to
rate their current health on a Visual Analog Scale (EQ-5D VAS).
These data were collected in 2005. RESULTS: Data on self-
reported quality of life were collected from 1335 patients from
France (n = 304), Germany (n = 247), Italy (n = 156), Spain (n
= 492), and the UK (n = 136). Most were outpatients (85%) and
most were aged 25–64 (87%); 57% were women. The most com-
monly reported reason for the physician visit was maintenance
(44%), followed by depressed (23%), manic (13%), hypomanic
(9%), and mixed (8%) health states. Mean (±standard deviation)
EQ-5D utility scores (76.0 ± 26.7) were greater than EQ-5D VAS
scores (63.2 ± 20.4). This relationship held across all countries.
EQ-5D utility and VAS scores were signiﬁcantly higher for
Germany (P < 0.01) and signiﬁcantly lower for Spain (P < 0.05).
Patients reporting depressed health state as the reason for their
visit had the lowest reported EQ-5D utility (64.2 ± 33.5) and
EQ-5D VAS (52.7 ± 21.3) scores. CONCLUSIONS: In this large,
multinational, cross-sectional survey of physicians and their
patients with bipolar disorder, patient-reported quality of life
varied by country and current phase of illness.
